Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity

Clinical Cancer Research

Volumn 14, Issue 1, 2008, Pages 169-177

  Kenter, Gemma G ^a   Welters, Marij J P ^a   Valentijn, A Rob P M ^a   Löwik, Margriet J G ^a   Berends van Der Meer, Dorien M A ^a   Vloon, Annelies P G ^a   Drijfhout, Jan W ^a   Wafelman, Amon R ^a   Oostendorp, Jaap ^a   Fleuren, Gert Jan ^a   Offringa, Rienk ^a   Van Der Burg, Sjoerd H ^a   Melief, Cornelis J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; MONTANIDE ISA 51; PROTEIN E6; PROTEIN E7; WART VIRUS VACCINE;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FLU LIKE SYNDROME; HALITOSIS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; MALAISE; NECROSIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RADICAL HYSTERECTOMY; SWELLING; T LYMPHOCYTE; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ADULT; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PEPTIDES; REPRESSOR PROTEINS; T-LYMPHOCYTES; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 40549129230     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1881     Document Type: Article

References (52)

1. Bosch XF, De Sanjosé S. Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr 2003;31:3-13.
2. Muñoz N, Bosch XF, De Sanjosé S, et al. Classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
3. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type16 vaccine. N Engl J Med 2002;21:1645-51.
4. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
5. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet 2005;6:271-8.
6. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
7. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
8. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
9. Mao C, Koutsky A, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. A randomized control trial. Obstet Gynecol 2006;107:18-27.
10. Schiller JT, Lowy DR. Prospects for cervical cancer prevention by human papillomavirus vaccination. Cancer Res 2006;66:10229-32.
11. Stanley MA. Human papillomavirus vaccines. Rev Med Virol 2006;16:139-49.
12. Zwaveling S, Ferreira Mota SC, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002;169:350-8.
13. Vambutas A, DeVoti J, Nouri M, et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 2005;23:5271-80.
14. de Jong A, van der Burg SH, Kwappenberg KM, et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002;62:472-9.
15. Welters MJP, de Jong A, van den Eeden SJF, et al. Frequent display of human papillomavirus type16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003;63:636-41.
16. + T-cell immunity against early antigens E2 and E6. Cancer Res 2004;64:5449-55.
17. + T-helper 1 immunity in relation to health versus disease. Int J Cancer 2006;118:950-6.
18. van Poelgeest MIE, Nijhuis ER, Kwappenberg KMC, et al. Distinct regulation and impact of type1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. Int J Cancer 2006;118:675-83.
19. van der Burg SH, Kwappenberg KMC, O'Neill T, et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 2001;19:3652-60.
20. deJong A, O'Neill T, Khan AY, et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 2002;20:3456-64.
21. Baldwin PJ, Van der Burg SH, Boswell CM, et al. Vaccinia-expressed human papillomavirus 16 and 18 E6 and E7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res 2003;9:5205-13.
22. Smyth LJC, van Poelgeest MIE, Davidson EJ, et al. Immunological responses in women with human papillomavirus type 16 (HPV-16) associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res 2004;10:2954-61.
23. + T-cell responses when immunizing with multiepitope peptide vaccines. J Immunother 1997;29:224-31.
24. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:269-70.
25. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005;115:739-46.
26. van Driel WJ, Ressing ME, Kenter GG, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 1999;35:946-52.
27. Ressing ME, Van Driel WJ, Brandt RM, et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 2000;23:255-66.
28. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy moving beyond current vaccines. Nat Med 2004;10:909-15.
29. + CTL priming by exact peptide-epitopes in IFA induces a vanishing CTL response, while long peptides induce sustained CTL reactivity. J Immunol 2007;179:5033-40.
30. Van der Burg SH, Bijker MS, Welters MJP, et al. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Adv Drug Deliv Rev 2006;58:916-30.
31. + T lymphocytes. Nature 2003;421:852-6.
32. + T cell memory via TRAIL mediated activation-induced cell death. Nature 2005;434:88-93.
33. + T-cell immunity in cervical cancer patients by an HPV16 E6 and E7 long-peptide vaccine. Clin Cancer Res 2008;14.
34. Pasquetto V, Bui H-H, Giannino R, et al. HLA-A* 0201, HLA-A*1101 and HLA-B*0702 transgenic mice recognize numerous poxvirus determinants from awide variety of viral gene products. J Immunol 2005;175:5504-15.
35. Jing L, Chong TM, McClurkan CL, et al. Diversity in the acute CD8 T cell response to vaccinia virus in humans. J Immunol 2005;175:7550-9.
36. McShane H, Hill A. Prime-boost immunization strategies for tuberculosis. Microbes Infect 2005;7:962-7.
37. Ferrara A, Nonn M, Sehr P, et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 2003;129:521-30.
38. Santin AD, Hermonat PL, Ravaggi A, et al. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 1999;73:5401-10.
39. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523-7.
40. + tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007;67:354-61.
41. + regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A 2007;104:12087-92.
42. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48.
43. Mehta AM, Jordanova ES, Van Wezel T, et al. Genetic variation of antigen processing machinery components and association with cervical carcinoma. Genes Chromosomes Cancer 2007;46:577-86.
44. Algarra I, Garcia-Lora A, Cabrera T, et al. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 2004;53:904-10.
45. Cao ZA, Daniel D, Hanahan D. Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer 2002;2:1-11.
46. Bracci L, Moschella F, Sestili P. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B cell and Tcell homeostatic proliferation and specific tumor infiltration. Clin Cancer Res 2007;13:644-53.
47. Lake RA, Robinson BW. Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 2005;5:397-405.
48. Nowak AK, Lake RA, Robinson BW. Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev 2006;58:975-90.
49. Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006;12:878-87.
50. Gabrilovich DI. Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. Lancet Oncol 2007;8:2-3.
51. Kaufmann AM, Stern PL, Rankin EM, et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 2002;8:3676-85.
52. Davidson EJ, Boswell CM, Sehr P, et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003;63:6032-41.